KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Cash from Operations (2020 - 2025)

Historic Cash from Operations for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to -$52.6 million.

  • AbCellera Biologics' Cash from Operations fell 8209.96% to -$52.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$104.6 million, marking a year-over-year increase of 1299.44%. This contributed to the annual value of -$108.6 million for FY2024, which is 14740.98% down from last year.
  • As of Q3 2025, AbCellera Biologics' Cash from Operations stood at -$52.6 million, which was down 8209.96% from -$32.4 million recorded in Q2 2025.
  • AbCellera Biologics' 5-year Cash from Operations high stood at $273.0 million for Q2 2022, and its period low was -$126.8 million during Q3 2022.
  • Moreover, its 5-year median value for Cash from Operations was -$11.6 million (2025), whereas its average is $14.4 million.
  • In the last 5 years, AbCellera Biologics' Cash from Operations surged by 1443835.08% in 2021 and then plummeted by 2714716.98% in 2024.
  • AbCellera Biologics' Cash from Operations (Quarter) stood at -$16.7 million in 2021, then soared by 284.97% to $30.9 million in 2022, then plummeted by 163.44% to -$19.6 million in 2023, then skyrocketed by 59.21% to -$8.0 million in 2024, then plummeted by 557.43% to -$52.6 million in 2025.
  • Its last three reported values are -$52.6 million in Q3 2025, -$32.4 million for Q2 2025, and -$11.6 million during Q1 2025.